Mineralys Therapeutics: Positive Q3 Results, Nearing FDA Submission

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded11 Nov 2025

Publisherfeeds.acast.com ↗

Handlerec:2198048

Show notes

Mineralys Therapeutics, a high blood pressure medicine developer, reported a smaller loss than expected in Q3, but stocks still fell due to investor concerns about drug approval. The companys loss per share decreased from 96 cents to 52 cents, aided by reduced R&D costs. Mineralys raised $287.5 million in September, ending Q3 with a $593.6 million cash reserve. CEO Jon Congleton expressed excitement, as the company prepares to submit its New Drug Application for lorundrostat, with initial results for obstructive sleep apnea trial expected in Q1 2026.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.